GRAIL reported a 43% year-over-year increase in revenue to $32.0 million for the second quarter of 2024. The company's strategic update includes reducing overall spend and focusing on core multi-cancer early detection priorities, which is expected to extend the cash runway into 2028.
Revenue in the second quarter was $32.0 million, representing 43% growth year over year.
Net loss for the quarter was $(1.6) billion, including amortization and impairment of acquisition-related intangible items.
Adjusted gross profit was $16.0 million.
Cash and cash equivalents totaled $958.8 million as of June 30, 2024.
GRAIL anticipates reducing its burn in 2025 to $325 million and expects $27 million in savings in 2024, net of anticipated severance and benefits costs.
Visualization of income flow from segment revenue to net income